Skip to content

Talk Bio

Actionable Insights Powered by AI

Subscribe
  • Privacy policy
  • Subscribe
  • Home
  • Phase 2 Clinical Trials
  • Page 4

Phase 2 Clinical Trials

  • Amino Acid, Peptide, or Protein
  • ENTITY
  • Immunologic Factor

BioNTech and Regeneron’s mRNA Cancer Vaccine Combo Clears Phase II in Melanoma

1 year ago talkbio0Tagged BioNTech, cemiplimab, Libtayo, melanoma, mRNA cancer, Phase 2 Clinical Trials, Regeneron, Tetravalent RNA-lipoplex Cancer Vaccine BNT111, Vaccines

BioNTech, Regeneron, mRNA cancer vaccine, Phase II trial, melanoma, BNT111, cemiplimab, Libtayo

Read More
  • Amino Acid, Peptide, or Protein
  • Disease or Syndrome
  • ORG

J&J Abandons Addex-Partnered Epilepsy Candidate After Phase II Failure

1 year ago talkbio0Tagged Epilepsy, Johnson & Johnson, nervous system disorder, Phase 2 Clinical Trials, Receptors, Metabotropic Glutamate

Addex Therapeutics, Johnson & Johnson, ADX71149, Epilepsy, Phase II Trial, Metabotropic Glutamate Receptor, Neurological Disorders

Read More
  • Amino Acid, Peptide, or Protein
  • Disease or Syndrome
  • ENTITY

J&J’s Tremfya Fails to Meet Primary Endpoint in Giant Cell Arteritis Trial

1 year ago talkbio0Tagged Giant Cell Arteritis, glucocorticoid-free remission, Johnson & Johnson, Phase 2 Clinical Trials, Primary Endpoint, Tremfya

Tremfya, Johnson & Johnson, Giant Cell Arteritis, Phase II Trial, Primary Endpoint, Glucocorticoid-Free Remission

Read More
  • Amino Acid, Peptide, or Protein
  • Biologically Active Substance
  • Disease or Syndrome

J&J’s Nipocalimab Shows Promise in Sjögren’s Disease with Significant Phase 2 Results

1 year ago talkbio0Tagged Autoimmune Diseases, FCGRT gene, Inhibitor, Johnson & Johnson, Nipocalimab, Phase 2 Clinical Trials, Sjögren 's disease

nipocalimab, Sjögren’s disease, Johnson & Johnson, Phase 2 study, autoimmune disease, FcRn inhibitor

Read More
  • ENTITY
  • Immunologic Factor
  • Neoplastic Process

AbbVie Achieves Early Return on Investment with $10 Billion Immunogen Acquisition Following Phase II Ovarian Cancer Success

1 year ago talkbio0Tagged AbbVie, Antibody-Drug Conjugates, Antigens, Elahere, ovarian neoplasm, Phase 2 Clinical Trials, Return on Investment, ROI

AbbVie, Immunogen, Ovarian Cancer, Phase II Trial, Return on Investment (ROI), Antibody-Drug Conjugate (ADC), Elahere

Read More
  • Disease or Syndrome
  • ENTITY
  • ORG

Revolutionary Oral Treatment for Retinal Disease Shows Promising Results in Phase II Trials

1 year ago talkbio0Tagged Oral treatment, Phase 2 Clinical Trials, Retinal Diseases, Revolutionary, Rezolutes

Retinal disease, oral treatment, Phase II trials, revolutionary, promising results, Rezolutes.

Read More
  • Amino Acid, Peptide, or Protein
  • Biomedical Occupation or Discipline
  • ENTITY

AltruBio Secures $225 Million for Phase II Trials of Novel Immune Checkpoint Enhancing Antibody

1 year ago talkbio0Tagged AltruBio, Antibodies, Biotechnology, Cancer Therapeutic Procedure, healthcare innovation, Immune, Immunotherapy, Phase 2 Clinical Trials

AltruBio, funding, Phase II trials, immune checkpoint enhancing antibody, cancer treatment, immunotherapy, biotechnology, healthcare innovation.

Read More
  • Disease or Syndrome
  • Functional Concept
  • Manufactured Object

CinDome Invests $40 Million in Phase II Clinical Trials for Gastroparesis Treatment

1 year ago talkbio0Tagged CinDome, development aspects, Gastroparesis, Investments, Medical Research activity, Phase 2 Clinical Trials

CinDome, gastroparesis, Phase II clinical trials, $40 million investment, medical research, treatment development.

Read More
  • Disease or Syndrome
  • ENTITY
  • Functional Concept

Addex Therapeutics’ Phase II Epilepsy Drug in Partnership with J&J Fails to Meet Endpoints

2 years ago talkbio0Tagged Clinical, development aspects, drug candidate, Epilepsy, J&J, Phase 2 Clinical Trials

Addex Therapeutics, J&J, Phase II trial, epilepsy, drug candidate, clinical endpoints, future development.

Read More
  • ENTITY
  • Mental or Behavioral Dysfunction
  • ORG

Neurocrine Biosciences and Takeda’s Collaborative Drug Shows Promising Results in Phase II Clinical Trial for Depression

2 years ago talkbio0Tagged Biosciences, drug candidate, Mental Depression, Neurocrine, Phase 2 Clinical Trials, Takeda

Neurocrine Biosciences, Takeda, drug candidate, Phase II clinical trial, depression, promising results.

Read More

Posts pagination

Previous 1 … 3 4 5 Next

Organizations

Agencies amgen AstraZeneca boehringer ingelheim Centers for Disease Control and Prevention (U.S.) Congress (U.S. Legislature) court Drug Industry European Medicines Agency genentech Government Health care facility Johnson and Johnson Moderna Novavax Partnership Pfizer Pharmacy Benefit Manager Pharmacy facility Roche (company) sandoz sanofi squibb United States Federal Trade Commission United States Food and Drug Administration World Health Organization

Concepts & Ideas

Accelerated Accelerated Approval Access accessibility Approved aspects of adverse effects asset Bankruptcy Benefit Capacity Capital Changing Chinese Language Clearance Clinical Data Combined commercial Complete Compound Contract agreement Cost Effectiveness development aspects Discontinuation (procedure) Diversity Dosage drug price Drug Shortage earnings Economic Inflation Effectiveness Efficiency Expectations Failed Failure (biologic function) Financial cost Financial savings financing characteristics Funding Generalized Health Identifier Improvement Increased Infrequent Legal Legal patent Long-term Moderate (severity modifier) New Drug Application Overall Survival Paroxysmal perioperative Phase 2 Phase 3 Prices Pricing Programs - Publication Format Progression-Free Survival Projections and Predictions Recommendation regulatory Review [Publication Type] rights Risk Series Statistical Significance Study on Hold subcutaneous Submission Symptoms aspect Toxicity aspects trends qualifier Variant Weekly

Procedures

Advice Cancer Therapeutic Procedure Cell Therapy Clinical Research Clinical Trials Combined Modality Therapy Confirmatory Trial Detection Drug Discovery Evaluation Gene Modification gene therapy HIV prevention Immunotherapy Injection of therapeutic agent Medical Research activity patient safety Pharmaceutical Services Pharmacotherapy Phase 2 Clinical Trials Phase 3 Clinical Trials Precision Medicine Prescription procedure Reparative closure research Telemedicine Vaccination

Occupations

Artificial Intelligence biology (field) Biotechnology Drug Development Genetic Medicine Global Health Immunology medical technology Neurology speciality Neuroscience discipline public health medicine (field) Science Science of genetics Technology

Disorders

Achondroplasia Acute onset pain Adverse event Amyotrophic Lateral Sclerosis Angioedemas, Hereditary Asthma Attention deficit hyperactivity disorder Autoimmune Diseases Brain Neoplasms Burning Mouth Syndrome Cardiomyopathies Cardiovascular Diseases Chronic Kidney Diseases Chronic Obstructive Airway Disease Colorectal Carcinoma COVID19 (disease) Dental Plaque Dermatitis, Atopic Diabetes Diabetes Mellitus, Non-Insulin-Dependent Disease Progression Eczema Epilepsy Esophageal Neoplasms Fibrosis Heart failure Hematologic Neoplasms Hemophilia A Hemophilia B Hereditary Diseases Hypoparathyroidism IGA Glomerulonephritis Infantile Severe Myoclonic Epilepsy Inflammation Inflammatory Bowel Diseases Inflammatory disorder Kidney Diseases leukemia Liver and Intrahepatic Biliary Tract Carcinoma Liver diseases Lung diseases Lupus Nephritis Lymphoma, Follicular Malignant neoplasm of breast Malignant neoplasm of endometrium Malignant neoplasm of lung Malignant neoplasm of prostate Malignant neoplasm of stomach Malignant neoplasm of urinary bladder Malignant Neoplasms Malignant tumor of cervix melanoma Mental Depression Mental deterioration Metabolic Diseases Multiple Acyl Coenzyme A Dehydrogenase Deficiency Multiple Myeloma Multiple Sclerosis Muscular Dystrophy Muscular Dystrophy, Duchenne Nance-Horan syndrome Narcolepsy Neoplasms Nerve Degeneration nervous system disorder Neurodegenerative Disorders Non-Small Cell Lung Carcinoma Nonalcoholic Steatohepatitis Obesity Paroxysmal nocturnal hemoglobinuria Post-Traumatic Stress Disorder Primary Biliary Cholangitis Psoriasis Pulmonary arterial hypertension Pulmonary Hypertension Reduced Schizophrenia Seizures Severe (severity modifier) Small cell carcinoma of lung Solid Neoplasm Spinal Muscular Atrophy Ulcerative Colitis Urinary tract infection Weight Loss

Objects

Arrowhead Facility (object) Investments Labels (device)

Chemicals & Drugs

Agonist agonists Antibiotics Antibodies Antibodies, Bispecific Antibody-Drug Conjugates Antineoplastic Agents Biological Factors Biosimilars BTK Inhibitor Cancer Vaccines Caplyta Clesrovimab Clustered Regularly Interspaced Short Palindromic Repeats Donanemab Dosage Forms Dupixent durvalumab Enhertu Epidermal Growth Factor Receptor Glucagon-Like Peptide-1 Receptor Glucagon-Like Peptide 1 Humira Imfinzi Immunologic Adjuvants Immunostimulating conjugate (antigen) Inhibitor inhibitors Insulin Jemperli Keytruda Lenacapavir Lumateperone Microbicides Midomafetamine Monoclonal Antibodies Mounjaro Nitroglycerin/Sodium Citrate/Ethanol Solution obinutuzumab Ocaliva Opdivo Ozempic patritumab Pediatric brand name pembrolizumab Primary Endpoint Radiopharmaceuticals RNA RNA, Messenger RNA, Small Interfering Rybrevant semaglutide Stelara Tagrisso Tecentriq therapeutic autologous dendritic cells tirzepatide Tremfya Trodelvy Vaccines Wegovy Weight-Loss Agents Zantac

Activities & Behaviors

Acquisition (action) Administration occupational activities Advisory Committees Agreement authorization Automation business career CEO Collaboration competition Continuance of life Drug Approval Industry Leadership Machine Learning Manufacture Mediation Medicare National Security Optimization production Rating (action) Rejection (Psychology) Relations Sales - occupational activity Settlement and Resettlement Success Withdraw (activity)

Geographic Areas

California China Japan Market North Carolina Singapore United States

Phenomena

Emergency Situation Motor function (observable entity) Safety

Living Beings

Adult Child Consumer European (ethnic group) HIV Ira (eukaryote) manager Partner in relationship Pet Animal Plants Respiratory syncytial virus

Anatomy

Cardiovascular system Carvykti Cells Liver Neurosecretory Systems T-Lymphocyte

Physiology

Biological Markers cellular targeting Cessation of life Decision Gene Expression Growth Hearing Immune response Menopause mental health Mutation Practice Experience Response process RNA Interference

Genes & Molecular Sequences

CSHL1 gene K-ras Oncogene PDCD1 gene PREP gene TIGIT gene TYK2 gene
Copyright © TalkBio 2024 Proudly powered by WordPress | Theme: ogma-blog by Mystery Themes.
  • Privacy policy
  • Subscribe